文献速递乳腺癌放疗放疗物理与技术

Halcyon与Trilogy双侧乳腺癌VMAT计划剂量学比较

Treatment planning comparison of volumetric modulated arc therapy with the trilogy and the Halcyon for bilateral breast cancer.
PubMed 文献 · Radiat Oncol · 2021-02-18

本研究在10例双侧乳腺癌患者CT图像上比较Halcyon与Trilogy的容积调强弧形治疗计划,处方剂量50 Gy/2 Gy分次。结果显示Halcyon全弧计划较部分弧计划更具剂量学优势,虽心脏平均剂量和皮肤剂量增加,但心脏亚结构及其他危及器官剂量与Trilogy相当,且显著缩短治疗时间。

要点

  • Halcyon全弧计划在双侧乳腺癌VMAT中剂量学优于部分弧计划。
  • Halcyon较Trilogy增加心脏平均剂量和皮肤剂量,但心脏亚结构剂量相当。
  • Halcyon显著缩短治疗时间。

核心结论

  • 对于Halcyon,全弧计划在双侧乳腺癌放疗中比部分弧计划具有更多剂量学优势。
  • 尽管心脏平均剂量和皮肤剂量增加,但心脏亚结构和其他危及器官剂量与Trilogy相当,且治疗时间显著缩短。

研究设计与样本

  • 在10例双侧乳腺癌患者的CT图像上设计四种不同设置野的Halcyon计划,并进行剂量学比较。
  • 设计Trilogy和Halcyon的全弧和部分弧计划,分别称为T-4arc、T-8arc、H-4arc和H-8arc。
  • 处方剂量为50 Gy,分次剂量2 Gy,所有计划使用Eclipse 15.5治疗计划系统设计。
  • 采用Bonferroni多重比较检验比较四种Halcyon计划,采用Mann-Whitney U检验比较同一加速器全弧与部分弧计划的剂量学差异。
  • 选择更优的Halcyon计划进一步比较Trilogy与Halcyon的计划质量和交付效率。

主要发现

  • 具有高质量兆伏级锥形束CT设置野的Halcyon计划较其他Halcyon设置计划增加了PTV的Dmean、D2和V107以及心脏、左心室和肺的V5和Dmean。
  • T-8arc计划较T-4arc计划显著降低心脏、肺和肝脏的平均剂量和低剂量体积。
  • H-8arc在心脏的V5、V20、V30、V40和Dmean,左心室的V20、V30、V40和Dmean,左前降支的V30、V40、Dmax和Dmean,以及肺的V5和V40上显著高于H-4arc(p < 0.05)。
  • 与Trilogy计划相比,Halcyon计划降低了心脏和左心室的高剂量体积,但增加了心脏平均剂量。
  • 左前降支剂量及肺的V20和V30在两种加速器间无显著差异。

关键数值与推荐

  • 处方剂量为50 Gy,分次剂量2 Gy。
  • H-8arc较H-4arc在心脏V5、V20、V30、V40和Dmean,左心室V20、V30、V40和Dmean,左前降支V30、V40、Dmax和Dmean,以及肺V5和V40上显著更高(p < 0.05)。

临床怎么用

  • 在双侧乳腺癌VMAT放疗中,Halcyon可优先考虑全弧计划而非部分弧计划。
  • 尽管Halcyon增加心脏平均剂量和皮肤剂量,但心脏亚结构剂量与Trilogy相当且治疗时间更短,可作为临床选择依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Halcyon is a new machine from the Varian company. The purpose of this study was to evaluate the dosimetry of the Halcyon in treatment of bilateral breast cancer with volumetric modulated arc therapy. METHODS: On CT images of 10 patients with bilateral breast cancer, four Halcyon plans with different setup fields were generated, and dosimetric comparisons using Bonferroni's multiple comparisons test were conducted among the four plans. Whole and partial arc plans on the Trilogy and the Halcyon, referred to as T-4arc, T-8arc, H-4arc and H-8arc, were designed. The prescription dose was 50 Gy in 2-Gy fractions. All plans were designed with the Eclipse version 15.5 treatment planning system. The dosimetric differences between whole and partial arc plans in the same accelerator were compared using the Mann-Whitney U test. The better Halcyon plan was selected for the further dosimetric comparison of the plan quality and delivery efficiency between the Trilogy and the Halcyon. RESULTS: Halcyon plans with high-quality megavoltage cone beam CT setup fields increased the Dmean, D2 and V107 of the planning target volume (PTV) and the V5 and Dmean of the heart, left ventricle (LV) and lungs compared with other Halcyon setup plans. The mean dose and low dose volume of the heart, lungs and liver were significantly decreased in T-8arc plans compared to T-4arc plans. In terms of the V5, V20, V30, V40 and Dmean of the heart, the V20, V30, V40 and Dmean of the LV, the V30, V40, Dmax and Dmean of the left anterior descending artery (LAD), and the V5 and V40 of lungs, H-8arc was significantly higher than H-4arc (p < 0.05). Compared with the Trilogy's plans, the Halcyon's plans reduced the high-dose volume of the heart and LV but increased the mean dose of the heart. For the dose of the LAD and the V20 and V30 of lungs, there was no significant difference between the two accelerators. Compared with the Trilogy, plans on the Halcyon significantly increased the skin dose but also significantly reduced the delivery time. CONCLUSION: For the Halcyon, the whole-arc plans have more dosimetric advantages than partial-arc plans in bilateral breast cancer radiotherapy. Although the mean dose of the heart and the skin dose are increased, the doses of the cardiac substructure and other OARs are comparable to the Trilogy, and the delivery time is significantly reduced.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sun T, Lin X, Zhang G, et al. Treatment planning comparison of volumetric modulated arc therapy with the trilogy and the Halcyon for bilateral breast cancer. Radiat Oncol. 2021. PMID: 33602267. doi:10.1186/s13014-021-01763-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。